Prostate cancer screening company Prostate Conditions Education Council (PCEC) said on Monday that it is providing free prostate cancer testing to men across the country following the recent fall in delayed diagnosis due to fewer doctor visits and reduced testing in the face of ongoing COVID-19 pandemic.
Prostate cancer is the second leading cause of cancer death in men, but easily treated when caught early, but too often it is not diagnosed early. The Council's new programme allows for men to gain access to a prostate specific antigen (PSA) blood test by visiting a national network for laboratories for the simple blood test and those who are unable to visit a laboratory. The free testing programme will take place during September and will continue throughout the fall season until the resources for the programme are depleted.
Additionally, the Council has aligned with at-home digital screening provider imaware to promote testing so that men can take assess their prostate cancer risk. The families can sign up for the free prostate cancer screening by visiting www.prostateevents.org.
Based in Houston, Texas, imaware has provided an essential healthcare service to thousands of Americans for COVID-19, cardiovascular disease, prostate cancer and autoimmune disorders.
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
InSysBio agrees new collaborative project with BeOne Medicines
Physiomics secures new modelling contract with Numab Therapeutics
Mabwell reports first patient dosed with 7MW4911 in US trial
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
Avacta secures FDA clearance for second pre|CISION oncology programme
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis